Health Enhancement Products Announced the Long Awaited Discovery of a Class of "Orally Active Agents" in Its Primary Product, ProAlgaZyme

SCOTTSDALE, AZ--(Marketwire - November 14, 2007) - Health Enhancement Products, Inc. (OTCBB: HEPI), announced today that the company has captured the active agents from it primary product ProAlgaZyme, and described it as a class of orally active agents which are responsible for the clinical activity. The company stated that the unusual proteins agents are still under development and that they are now determining the individual components responsible for these observed positive clinical activities. The company plans to begin active discussions with large pharmaceutical and veterinary medicine companies in earnest in early 2008, to exploit the attractive drug development opportunities offered by the orally active unusual protein agents.

The company also announced that one of its key patent applications covering the composition of ProAlgaZyme has been published by the US patent office.

About Health Enhancement Products, Inc. and ProAlgaZyme

Health Enhancement Products Inc. is a nutraceutical company engaged in the development of a Dietary Supplement product using only pure, all-natural ingredients. The company's sole product is ProAlgaZyme, a liquid product produced from algae grown in 100% distilled water. The liquid in which the algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme. HEPI Pharmaceuticals, Inc. is exploring the development of the potential pharmaceutical applications of ProAlgaZyme.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, our inability to obtain regulatory approvals necessary to market and sell PAZ as a pharmaceutical, and the company's ability to secure funding, including for the subsidiary's pharmaceutical development of PAZ. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

Contact Information: For more information, please visit www.heponline.com. Contact information: John Gorman Email Contact: 480-385-3800